In 2026, the fight against cancer has become a "dynamic chase" thanks to the widespread use of Reverse Phase Protein Microarrays (RPPA). A major trend in the protein chip market is the use of these chips to monitor how a tumor's protein signaling changes during treatment. Unlike traditional biopsies that provide a "static" snapshot, RPPA allows doctors to track the "active" pathways that a...